Core Insights - Anixa Biosciences is focused on cancer treatment and prevention, featuring its Chairman and CEO, Dr. Amit Kumar, on the Water Tower Research Healthcare Happenings podcast to discuss positive clinical trial data for its breast cancer vaccine and ovarian cancer CAR-T therapy [1] Company Overview - Anixa Biosciences, Inc. is a clinical-stage biotechnology company specializing in cancer treatment and prevention [1] - The company's therapeutic portfolio includes liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy developed in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology [1] - Anixa's vaccine portfolio includes vaccines for breast and ovarian cancer developed with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [1] Technology and Collaboration - The CAR-T technology used by Anixa is differentiated by its mechanism, where the natural ligand of the FSHR receptor binds to tumor cells instead of using an antibody fragment [1] - Anixa partners with renowned research institutions to explore emerging technologies for further development and commercialization [1] Financial and Future Outlook - Dr. Kumar discussed the financial condition of the company and future plans during the podcast, indicating a focus on advancing their clinical programs [1]

Core Insights - Anixa Biosciences, Inc. is participating in the Water Tower Research Fireside Chat Series on December 15, 2025, with CEO Dr. Amit Kumar as a speaker [1][2] - The company focuses on cancer treatment and prevention, with a notable emphasis on ovarian cancer immunotherapy and vaccine development [2] Company Overview - Anixa is a clinical-stage biotechnology company specializing in cancer treatment and prevention [2] - The company is developing an ovarian cancer immunotherapy program in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) [2] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers like lung, colon, and prostate [2] - The vaccines target "retired" proteins expressed in certain cancers, with exclusive licensing agreements in place with Cleveland Clinic for breast and ovarian cancer vaccines [2] Upcoming Events - The Fireside Chat will be hosted by Robert Sassoon, Managing Director – Healthcare at Water Tower Research, and is open to all investors [2] - Final data from Anixa's Phase 1 breast cancer vaccine trial will be presented on December 11, 2025, at the San Antonio Breast Cancer Symposium [5]

Core Insights - Anixa Biosciences, Inc. will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025, in New York City [1][2] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [2] - The company utilizes a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) technology, which differentiates itself by using the natural ligand of the FSHR receptor, FSH, to bind to tumor cells [2] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [2] - The vaccines are based on immunizing against "retired" proteins expressed in certain cancer forms, with Cleveland Clinic entitled to royalties and commercialization revenues from these technologies [2] - Anixa's business model involves partnerships with renowned research institutions at all development stages, allowing the company to explore emerging technologies for further development and commercialization [2]

Core Viewpoint - Anixa Biosciences, Inc. is set to host an investor webcast on June 26, 2025, to discuss its business strategy, therapeutic portfolio, market opportunities, and upcoming milestones [1][2]. Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention [4]. - The company is developing an ovarian cancer immunotherapy program in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) technology [4]. - Anixa's vaccine portfolio includes vaccines for breast and ovarian cancer developed with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [4]. - The company partners with renowned research institutions to explore emerging technologies for development and commercialization [4]. Webcast Details - The webcast will feature an introductory presentation by Dr. Amit Kumar, Anixa's Chairman and CEO, followed by a Q&A session for investors [2]. - Interested participants must pre-register to listen to the webcast and ask questions during the live event [3].